NUCLEAR FACTOR-KAPPA B ACTIVATION: PHOSPHORYLATION AND ACETYLATION
==================================================================

The transcriptional factor nuclear factor kappa B (NF-κB) is a main regulator of the induction of several genes including inflammatory and immune response genes and the proliferation and death of cancer cells \[[@b1-inj-1632718-359]-[@b4-inj-1632718-359]\]. Cellular stimulation by pro-inflammatory cytokines, gram-negative bacterial lipopolysaccharide (LPS), viral infection, radiation, and hypoxia is induced by IκB kinase (IKK) complex-mediated IκB phosphorylation (predominant form, IKKβ) and ubiquitination, and degradation \[[@b5-inj-1632718-359]-[@b10-inj-1632718-359]\]. The mammalian NF-κB family consists of 5 subunits, p50-NF-κB1, p52-NF-κB2, c-Rel, p65-RelA, and RelB, which forms homo- or heterodimers of functional complexes.

NF-κB activity is regulated by its subcellular localization in the cytoplasm or nucleus. The NF-κB dimer is mainly sequestered in the cytoplasm as a complex associated with the IκB inhibitor in unstimulated resting cells, or rarely in the nucleus as a transcriptionally inactive complex shuttle \[[@b11-inj-1632718-359]\]. In activated cells, IκB-free NF-κB translocates into the nucleus where it activates the transcription of several genes, including newly synthesized IκB. In addition to translocation of NF-κB, the transcriptional activities of NF-κB are regulated by posttranslational modifications such as phosphorylation and acetylation of p65-NF-κB subunit for full activation \[[@b12-inj-1632718-359]-[@b14-inj-1632718-359]\]. The transcriptional activities of p65-NF-κB, which are specifically targeted by several kinases, are highly enhanced by phosphorylation of Ser^536^, or Ser^276^, and Ser^311^ (by zetaPKC) in association with the coactivator CBP/p300 \[[@b15-inj-1632718-359],[@b16-inj-1632718-359]\]. Additionally, Anrather et al. \[[@b17-inj-1632718-359]\] reported 3 phosphorylation sites at Ser^205^ (induced by LPS), Ser^276^ (by MSK1), and Ser^281^ (by LPS and unknown kinase) as essential phosphorylation sites for transcriptional activity.

Phosphorylation of p65-NF-κB at Ser^536^ leads to nuclear translocation or cytoplasmic priming, and the transactivation mechanism is the target of several kinases including the important kinase IKKβ \[[@b18-inj-1632718-359]-[@b20-inj-1632718-359]\]. Phosphorylation of Ser^281^ has been studied with other related phosphorylation sites, including Ser^205^ and Ser^276^, to evaluate transactivation \[[@b17-inj-1632718-359],[@b21-inj-1632718-359]-[@b23-inj-1632718-359]\]. Anrather et al. \[[@b17-inj-1632718-359]\] identified Ser^205^, Ser^276^, and Ser^281^ as potential phospho-acceptor sites within the p65 Rel homology domain, and found that both Ser^205^ and Ser^276^ can be mediated by Ser/Thr kinases, but Ser^281^ Ser-specific kinases alter transcriptional NF-κB activities when Ser is substituted with Thr. They suggested that the phosphorylation levels of these potential sites can affect the interaction of NF-κB with coactivators, and to acetylation patterns for the full NF-κB transcriptional activities. Additionally, p65-NF-κB phosphorylation levels reflect the differential NF-κB transcriptional activity of related gene subsets; however, phosphorylation is not essential for NF-κB DNA binding \[[@b23-inj-1632718-359]\]. It was previously shown that the transcriptional coactivators p300 and CBP mainly acetylate p65-NF-κB Lys^218^, Lys^221^, and Lys^310n^ \[[@b24-inj-1632718-359],[@b25-inj-1632718-359]\]. Particularly, p65-NF-κB Lys^310^ acetylation stimulates the full transcriptional activity of p65-NF-κB, but is only minimally related to DNA binding or IκB assembly.

AMPK ACTIVATION
===============

5'-AMP-activated protein kinase (AMPK) is a highly conserved serine/threonine protein kinase that regulates energy homeostasis and metabolic stress, and exists in all eukaryotic cells as heterotrimeric complexes comprising catalytic α-subunits and regulatory β- and γ-subunits. Phosphorylation of the Thr^172^ residue of the α subunit is important for maximum AMPK activity \[[@b26-inj-1632718-359]-[@b28-inj-1632718-359]\]. Three upstream kinases have been shown to activate AMPK. LKB1 stimulates AMPK in response to changes in the cellular AMP/ATP ratio, calmodulin-dependent protein kinase kinase β in response to intracellular Ca^2+^ concentration, and transforming growth factor-beta-activating kinase 1 by immunological cytokines \[[@b29-inj-1632718-359]-[@b32-inj-1632718-359]\].

INTERACTIONS BETWEEN NF-κB INDUCTION AND AMPK ACTIVATION
========================================================

In recent years, numerous studies have reported the effects of AMPK activities on inflammatory NF-κB activity \[[@b33-inj-1632718-359]-[@b48-inj-1632718-359]\]. The major function of AMPK in inhibiting inflammation has been demonstrated using a known AMPK activator and the pharmacological mimetic 5´-aminoimidazole-4-carboxamide ribonucleotide (AICAR). Other studies showed that AICAR inhibits tumor necrosis factor (TNF)-α and interleukin-β-induced NF-κB activities in immune cells \[[@b49-inj-1632718-359]-[@b52-inj-1632718-359]\] and inducible nitric oxide synthase and cyclooxygenase (COX-2) expression levels in LPSor cytokine-stimulated myocytes, adipocytes, or macrophages grown in culture \[[@b53-inj-1632718-359],[@b54-inj-1632718-359]\]. However, the anti-inflammatory effects of AICAR were also found to be AMPK-independent or nonspecific activators of AMPK in several studies \[[@b52-inj-1632718-359],[@b55-inj-1632718-359]\].

In addition to AICAR, there are several AMPK activators; metformin, used to treat type 2 diabetes; berberine, a natural product used in traditional Chinese medicine; and A-769662, derived from a high-throughput screen for AMPK activators \[[@b56-inj-1632718-359],[@b57-inj-1632718-359]\]. Aspirin and salicylate also inhibit the inflammatory NF-κB pathway, and it has been proposed that this results from inhibition of the upstream kinase IKK-β \[[@b58-inj-1632718-359]\]. However, they suggested that inhibition of the NF-κB pathway is mediated by AMPK activation, rather than by direct inhibition of IKK-β. Overall, all AMPK activators described above have been reported to inhibit inflammatory responses in various model systems.

Example 1 (Unpublished): Effects of AMPK Activator on LPS- or Hypoxia-Induced NF-κB Phosphorylation and Acetylation Activities in the Human Bladder Cancer Cell Line T24
------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We recently investigated the effects of LPS and the AMPK activator AICAR on COX-2 induction, two specific p65-NF-κB phospho-activities (Ser^536^ and Ser^281^), and the acetylation activity of p65-NF-κB Lys^310^. Particularly, we proposed that the expression levels of p65-NF-κB Ser^281^ phosphorylation and p65-NF-κB Lys^310^ acetylation were inversed, suggesting potential inhibitory activity of p65-NF-κB Ser^281^ phosphorylation. Both LPSand hypoxia-induced NF-κB activities in a human bladder cancer line T24 were alleviated by pretreatment with AICAR. Additionally, AMPK siRNA-mediated suppression enhanced NF-κB-mediated COX-2 induction by LPS or hypoxia. Particularly, we suggested that direct interactions and colocalization occur between p-AMPK (at phospho-activation site Thr^172^) (p-AMPK) and IκBα-free NF-κB, especially in nucleus. LPS-induced full transcriptional activity of NF-κB, as indicated by a critical acetylation level (Ac-K310 p65-NF-κB), was decreased by AICAR pretreatment, whereas the phosphorylation level at p65-NF-κB Ser^281^ was increased \[[@b35-inj-1632718-359]\].

Example 2 (Unpublished): Transient Inactivation of AMPK and ROS Participation After LPS Treatment in the Human Bladder Cancer Line T24
--------------------------------------------------------------------------------------------------------------------------------------

We also found that AMPK phosphorylation as well as the ability of AICAR to enhance phosphorylation of AMPK was decreased only at the early time (\~1 hour) after LPS stimulation. This effect of LPS stimulation on p-AMPK levels was abolished or showed a greater increase at the later time (after 16 hours). Recently, Sag et al. \[[@b59-inj-1632718-359]\] and Tadie et al. \[[@b60-inj-1632718-359]\] demonstrated that the transient suppression of AMPK phosphorylation diminished the ability of AICAR to increase AMPK phosphorylation in LPS-stimulated cells. In particular, Tadie et al. \[[@b60-inj-1632718-359]\] suggested that HMGB1 released form injured or necrotic cells was involved in decreasing LPS-treated AMPK phospho-activity based on their results showing an inverse relationship between accumulated HMGB1 in cytoplasm and AMPK phosphorylation levels. Furthermore, we examined N-acetyl cystein (NAC) pretreatment under the above experimental conditions to immediately inhibit reactive oxygen species (ROS) release at the early time, which resulted in increased p-AMPK levels and decreased COX-2 induction. Thus, our finding may also be explained by the influence of early released ROS on AMPK phospho-activity in LPS-stimulated bladder cancer cells.

Based on our findings, AICAR pretreatment partially decreased both LPS- and hypoxia-treated COX-2 induction. Additionally, LPS-induced NF-κB p65 Ser^536^ phospho-activity was decreased by AICAR pretreatment, but highly increased by AMPK-siRNA, suggesting an AMPK-dependent mechanism. Consistent with this result, recent studies reported the ability of AICAR to suppress NF-κB activation in response to LPS or pro-inflammatory cytokines through an AMPK-dependent or -independent mechanism \[[@b52-inj-1632718-359],[@b59-inj-1632718-359]-[@b61-inj-1632718-359]\].

Example 3 (Unpublished): Differential Activities of AMPK and Activation of NF-κB Signaling Pathways Under Inflammatory or Hypoxia Conditions
--------------------------------------------------------------------------------------------------------------------------------------------

It is generally known that the TLR4/NF-κB signaling pathway is activated under hypoxic conditions, increasing the gene expression of downstream inflammatory mediators \[[@b7-inj-1632718-359],[@b8-inj-1632718-359],[@b57-inj-1632718-359],[@b62-inj-1632718-359]-[@b67-inj-1632718-359]\]. Additionally, hypoxia induces AMPK activation in cancer cells as a survival mechanism by ATP-depletion (Laderoute et al. \[[@b66-inj-1632718-359]\], 2006; Miller et al. \[[@b67-inj-1632718-359]\], 2008; Kim et al. \[[@b57-inj-1632718-359]\], 2012). In contrast, the phospho-activities of the serial enzymes p-LKB1, p-AMPK, and p-ACC in our study were time-dependently diminished under hypoxia conditions and HIF1α expression was increased (unpublished). In addition, p-AMPK levels after LPS, AICAR, or NAC treatment and even in untreated cells were decreased under hypoxia conditions, and hypoxia-induced COX-2 expression was synergistically enhanced by additional treatment with LPS and blocked or decreased by AICAR pretreatment; these results are similar to those of other recent reports \[[@b9-inj-1632718-359],[@b10-inj-1632718-359]\].

CONCLUSIONS
===========

In this short review, we highlighted the regulatory interactions of AMPK activity on NF-κB induction, particularly in post-translational phosphorylation and acetylation of NF-κB under inflammatory conditions or in hypoxia environments, providing examples in the human bladder cancer cell line T24.
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